ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q4 2023 Earnings Call Transcript

Francois Michelon: Thanks Mike. And Ed, just to tag on an extra bit of reaffirming some of what we’ve said, the CE mark enables us to sell the product in Europe. But as I mentioned, having a body of clinical evidence from local users in each target market is the missing link. And so that’s clearly what we and other companies do and King’s College being a good example of that, will be a source of data. We’ll be able to bring our potential customers in the UK to visit that site. They’ll be able to see the system on the ground in the UK. They’ll be able to eventually review the data from that study. And we’ll do the same in Germany, in France and other markets. So the CE mark is a great starting point. I think it reflects the product quality. And combined with the clinical data that we’re building, that will lead to commercialization. And in parallel, certainly, same thing will happen here in the U.S. with the FDA. I hope that’s helpful.

Edward Woo: Yes. That was very helpful. Thank you very much for answering those questions, and again, I wish you guys, good luck. Thank you.

Francois Michelon: Thank you so much.

Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Francois for any closing remarks.

Francois Michelon: Yes. Thank you, operator. And thank you to my team and to the listeners today for listening to our progress. I’ll close the call and wish everyone a good long Easter weekend, if you’re celebrating Easter. And looking forward to updating everyone with news as we progress. Thank you. Bye-bye.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.